Given the heterogeneity of this brain disease, available pharmacological treatments are effective only for a small group of people
Some PBMs are receptive to input
Safety monitoring is also crucial while probiotics and FMT have been safe in trials so far, there is a theoretical risk of introducing infections or causing undesired immune reactions, especially in patients with immune dysfunction (like those on MS immunosuppressants)
The difference is that peptides are smaller, more targeted, and act as messenger molecules that communicate with certain cells/tissues and tell them what to do
Both components maintain stability under standard peptide storage conditions
Pyroglutamic Acidosis OVERVIEW Pyroglutamic acidosis is a rare cause of high anion gap metabolic acidosis (HAGMA) pyroglutamic acid is also known as 5-oxoprolinemia produced from -glutamyl cysteine by the enzyme -glutamyl cyclotransferase catabolised by 5-oxoprolinase when glutathione levels are low, the activity of -glutamyl cyclotransferase is increased, resulting in pyroglutamic acid accumulation in glutathione-depleted states CAUSE Risk factors elderly paracetamol use (glutathione depletion by its metabolite NAPQI) sepsis (depletion of glutathione) flucloxacillin (inhibits 5-oxoprolinase) hepatic and renal impairment malnutrition pregnancy vigabatrin congenital enzyme deficiencies (glutathione synthase deficiency) Pyroglutamic acidosis results from disruption of the -glutamyl cycle 5-oxoproline (aka pyroglutamic acid) is produced from -glutamyl cysteine by the enzyme -glutamyl cyclotransferase -glutamyl cyclotransferase activity increases when glutathione levels are low, due to a loss of feedback inhibition from glutathione accumulation of pyroglutamic acid is thought to be due to depletion of the glutathione, particularly when glutathione synthetase is inhibited Decreased activity of 5-oxoprolinase, which breaks down pyroglutamic acid, may also play a role CLINICAL FEATURES manifestations of acidaemia e.g
